Global Template
Primary Author(s)
Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.
Cancer Category/Type
Put your text here
Cancer Sub-Classification / Subtype
Put your text here
Definition / Description of Disease
Put your text here
Synonyms / Terminology
Put your text here
Epidemiology / Prevalence
Put your text here
Clinical Features
Put your text here
Sites of Involvement
Put your text here
Morphologic Features
Put your text here
Immunophenotype
Put your text here or fill in the table
| Finding | Marker |
|---|---|
| Positive (universal) | CD1 |
| Positive (subset) | CD2 |
| Negative (universal) | CD3 |
| Negative (subset) | CD4 |
Additional Description:
Put your text here
Chromosomal Rearrangements (Gene Fusions)
Put your text here or fill in the table
| Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | Pathogenic Derivative | Prevalence |
|---|---|---|---|
| t(9;22) | BCR-ABL1 | der(22) | 5% |
| t(8;21) | RUNX1-RUNXT1 | der(8) | 5% |
Additional Description:
Put your text here
Characteristic Chromosomal Aberrations / Patterns
Put your text here
Genomic Gain/Loss/LOH
Put your text here or fill in the table
| Chromosome Number | Gain/Loss/Amp/LOH | Region |
|---|---|---|
| 8 | Gain | chr8:0-1000000 |
| 7 | Loss | chr7:0-1000000 |
Additional Description:
Put your text here
Gene Mutations (SNV/INDEL)
Put your text here or fill in the table
| Gene | Mutation | Oncogene/Tumor Suppressor/Other | Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) | Prevalence (COSMIC/TCGA/Other) |
|---|---|---|---|---|
| TP53 | R273H | Tumor Suppressor | LOF | 20% |
Additional Description:
- Other Mutations
Put your text here
- Concomitant Mutations
Put your text here
- Secondary Mutations
Put your text here
- Mutually Exclusive
Put your text here
Epigenomics (Methylation)
Put your text here
Genes and Main Pathways Involved
Put your text here
Diagnostic Testing Methods
Put your text here
Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)
Put your text here
Familial Forms
Put your text here
Other Information
Put your text here
Links
Put your links here
References
Reference Example, BOOK
- Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.
Reference Example, Journal Article
- Li Y, Mehta PK, Nizetic D, Kaneko Y, Chan GCF, Chan LC, Squire J, Scherer SW and Hitzler JK (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691.